PRPH vs. ABEO, PMVP, GNLX, ALLK, DMAC, SLS, ORMP, BTAI, MIST, and IOBT
Should you be buying ProPhase Labs stock or one of its competitors? The main competitors of ProPhase Labs include Abeona Therapeutics (ABEO), PMV Pharmaceuticals (PMVP), Genelux (GNLX), Allakos (ALLK), DiaMedica Therapeutics (DMAC), SELLAS Life Sciences Group (SLS), Oramed Pharmaceuticals (ORMP), BioXcel Therapeutics (BTAI), Milestone Pharmaceuticals (MIST), and IO Biotech (IOBT). These companies are all part of the "pharmaceutical preparations" industry.
Abeona Therapeutics (NASDAQ:ABEO) and ProPhase Labs (NASDAQ:PRPH) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, community ranking, institutional ownership, analyst recommendations, risk, earnings and profitability.
Abeona Therapeutics currently has a consensus target price of $36.00, suggesting a potential upside of 1,035.65%. ProPhase Labs has a consensus target price of $11.00, suggesting a potential upside of 117.39%. Given ProPhase Labs' higher probable upside, research analysts clearly believe Abeona Therapeutics is more favorable than ProPhase Labs.
Abeona Therapeutics received 399 more outperform votes than ProPhase Labs when rated by MarketBeat users. Likewise, 70.27% of users gave Abeona Therapeutics an outperform vote while only 50.44% of users gave ProPhase Labs an outperform vote.
In the previous week, Abeona Therapeutics had 9 more articles in the media than ProPhase Labs. MarketBeat recorded 14 mentions for Abeona Therapeutics and 5 mentions for ProPhase Labs. Abeona Therapeutics' average media sentiment score of 1.43 beat ProPhase Labs' score of -0.14 indicating that ProPhase Labs is being referred to more favorably in the news media.
Abeona Therapeutics has a beta of 1.49, meaning that its stock price is 49% more volatile than the S&P 500. Comparatively, ProPhase Labs has a beta of -0.29, meaning that its stock price is 129% less volatile than the S&P 500.
ProPhase Labs has higher revenue and earnings than Abeona Therapeutics. ProPhase Labs is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.
Abeona Therapeutics has a net margin of 0.00% compared to Abeona Therapeutics' net margin of -37.81%. Abeona Therapeutics' return on equity of -29.83% beat ProPhase Labs' return on equity.
80.6% of Abeona Therapeutics shares are owned by institutional investors. Comparatively, 9.5% of ProPhase Labs shares are owned by institutional investors. 5.3% of Abeona Therapeutics shares are owned by company insiders. Comparatively, 26.1% of ProPhase Labs shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Abeona Therapeutics beats ProPhase Labs on 9 of the 16 factors compared between the two stocks.
Get ProPhase Labs News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ProPhase Labs Competitors List
Related Companies and Tools
